耐受性
医学
不利影响
安慰剂
麻醉
腰骶关节
随机对照试验
临床试验
神经病理性疼痛
背根神经节
背景(考古学)
内科学
安全概况
背痛
慢性疼痛
外科
坐骨神经痛
生命体征
加药
腰痛
临床实习
作者
Todd Bertoch,Haeun Park,Jina Kim,Enoch Seo,Hyejin Kho,Jung Jong Cho,Sun Jin Kim
出处
期刊:Pain reports
[Wolters Kluwer]
日期:2026-05-13
卷期号:11 (3)
标识
DOI:10.1097/pr9.0000000000001441
摘要
Abstract Introduction: Neuropathic pain (NP) management remains challenging owing to the suboptimal efficacy and short durability of current therapies. Poor clinical outcomes and persistent peripheral NP from lumbosacral radiculopathy (NP-LSR) highlight the need for novel pain management approaches. KLS-2031 is a novel gene therapy that uses recombinant adeno-associated virus serotype 5 vectors to deliver therapeutic genes directly to the dorsal root ganglion through a single transforaminal epidural injection. Objectives: To evaluate the safety, tolerability, and exploratory efficacy of KLS-2031 in patients with NP-LSR. Methods: In this first-in-human, randomized, placebo-controlled phase 1/2a study (double-blinded until week 52 and open-label extension through week 104; ClinicalTrials.gov: NCT04238793), 18 patients were randomized to receive KLS-2031 (n = 12, doses of 1 × 10 11 , 10 12 , and 10 13 VG/500 µL in cohorts 1, 2, and 3, respectively) or placebo (n = 6). Primary endpoints were safety and tolerability that were assessed through week 52. Results: KLS-2031 was well-tolerated across all dose levels, with no reports of mortality, serious treatment-emergent adverse events (TEAEs), or AE-related discontinuations. The proportion of patients experiencing drug-related TEAEs was comparable between the KLS-2031 and placebo groups. No clinically significant safety signals were observed in other safety assessments. Exploratory efficacy outcomes did not show a consistent trend favoring KLS-2031 over placebo. Conclusion: KLS-2031 demonstrated a favorable safety profile and tolerability in patients with NP-LSR, supporting the need for further studies to confirm its safety and efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI